When was Prilenia founded?

Prilenia was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Prilenia located?

Prilenia is headquartered in Herzliya, Israel.

Who is the current CEO of Prilenia?

Michael R Hayden of Prilenia. They have also founded 1 company.

How many employees does Prilenia have?

As of Jun 30, 2026, the latest employee count at Prilenia is 61.

Is Prilenia a funded company?

Prilenia is a funded company, having raised a total of $134M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 03, 2020.

When was the latest funding round of Prilenia?

Prilenia's latest funding was a $***** Series B round on Nov 03, 2021, with participation from 8 investors. Its primary sector is Neurology. In Israel, the Neurology sector has seen $59.1M in funding in 2026 to date.

Where does Prilenia rank among its competitors?

Prilenia ranks 246th amongst 2861 active competitors, of which 973 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Prilenia?

Prilenia's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Prilenia - 2026 Company Profile, Team, Funding & Competitors

Prilenia is a series B company based in Herzliya (Israel), founded in 2018 by Michael R Hayden. It operates as a Developer of therapeutics for the treatment of neurogenerative diseases. Prilenia has raised $134M in funding from Forbion and Amplitude. The company has 2861 active competitors, including 973 funded and 710 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of therapeutics for the treatment of neurogenerative diseases. It has developed its lead product Pridopidine, a sigma-1 receptor (S1R) agonist, for the treatment of multiple movement disorders and neurodegenerative diseases in adults and children. The compound is also shown to treat Huntington's disease (phase III), ALS, Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and other conditions.

Website: prilenia.com
Social
Email ID: *****@prilenia.com
Phone Number: +972 **********

Key Metrics

Founded Year

2018

Location

Herzliya, Israel

Stage

Series B

Total Funding

$134M in 2 rounds

Latest Funding Round

Series B, Nov 03, 2021, $*****

Investors

Forbion & 9 more

Ranked

246^th among 2861 active competitors

Employee Count

61 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 577 more

View Prilenia's full profile

Prilenia has raised a total funding of $134M over 2 rounds. Its first funding round was on Jun 03, 2020. Its latest funding round was a Series B round on Nov 03, 2021 for $*****. 8 investors participated in its latest round. Prilenia has 10 institutional investors.

Here is the list of recent funding rounds of Prilenia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 03, 2021	5310692	Series B	7287695	9476837	9653887	1595789
Jun 03, 2020	8552960	Series A	8362595	1365560	Forbion	Talisman Capital Partners & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Prilenia's funding rounds and investors

The founders of Prilenia is Michael R Hayden. Michael R Hayden is the CEO of Prilenia.

Here are the details of Prilenia's key team members:

Michael R Hayden: Founder & CEO of Prilenia.
Contact Info: 1 email address

View details of Prilenia's Founder profiles and Board Members

Prilenia's employee count trend

Prilenia has 61 employees as of Jun 26. Here is Prilenia's employee count trend over the years:

Uncover Prilenia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prilenia include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Prilenia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
246th	Prilenia 2018, Herzliya (Israel), Series B	Developer of therapeutics for the treatment of neurogenerative diseases	$134M	Sectoral, Amplitude & 8 others	57/100